Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.73 |
| ▸ | SQLE | Q14534 | 7/20 | 0.64 |
| ▸ | MAPT | P10636 | 2/20 | 0.64 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | FNTA | P49354 | 1/20 | 0.52 |
| ▸ | FNTB | P49356 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2769830 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL20624673 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL30531903 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL11892318 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL21260659 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL30531904 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL2495183 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL2495184 | 1.00 | KMT2A (0.73) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| Hydrochloric Acid SCHEMBL8940577 | 0.98 | KMT2A (0.70) | KMT2ASQLEMAPTMEN1CYP3A4 | |
| SCHEMBL352058 | 0.98 | KMT2A (0.68) | KMT2ASQLEMAPTMEN1CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115433728-B | Eugenia caryophyllata sesquiterpene synthase and application thereof | 中国中医科学院中药研究所 | 2024-11-05 | — | — | CN | claimed |
| CN-118853643-A | Biota orientalis sesquiterpene synthase PoTPS1 and encoding gene and application thereof | 北京化工大学 | 2024-10-29 | — | — | CN | claimed |
| CN-117986069-A | Method for producing squalene and squalane based on farnesene fermentation broth and application of method | 中国科学院青岛生物能源与过程研究所 | 2024-05-07 | — | — | CN | claimed |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2022-01-20 | — | — | US | claimed |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2021-09-23 | — | — | US | claimed |
| US-20190284125-A1 | Amine Derivatives of The Beta-Farnesene | CLARIANT INTERNATIONAL LTD. (CH) | 2019-09-19 | — | — | US | claimed |
| US-10201510-B2 | Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for convulsive seizure | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2019-02-12 | — | — | US | claimed |
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | THE GENERAL HOSPITAL CORPORATION | 2012-07-05 | — | — | US | claimed |
| EP-2451944-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | President and Fellows of Harvard College (US) | 2012-05-16 | — | — | EP | claimed |
| WO-2011006073-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-01-13 | — | — | WO | claimed |
| US-20080286209-A1 | Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2008-11-20 | — | — | US | claimed |
| WO-2006086372-A2 | COMPOSITIONS AND METHODS FOR TREATMENT OF NEUROLOGICAL SYMPTOMS ASSOCIATED WITH ALCOHOL-WITHDRAWAL AND FOR CONVULSIVE SEIZURE | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2006-08-17 | — | — | WO | claimed |
| JP-57106644-A | — | — | None | — | — | JP | disclosed |
| JP-10218764-A | — | — | None | — | — | JP | disclosed |
| JP-11130670-A | — | — | None | — | — | JP | disclosed |
| CN-114746434-B | Antibiotic compounds | 莱顿大学 | 2025-02-21 | — | — | CN | disclosed |
| EP-0194901-A2 | Isoprenoidamine derivatives, compositions containing them, their preparation, and their use | SHIONOGI & CO., LTD. (JP) | 1986-09-17 | — | — | EP | disclosed |
| US-4520029-A | ANTIINFLAMMATORY AND ANTIULCER AGENTS | KOTOBUKI SEIYAKU CO., LTD. (JP) | 1985-05-28 | — | — | US | disclosed |
| US-4520029-A | ANTIINFLAMMATORY AND ANTIULCER AGENTS | KOTOBUKI SEIYAKU CO., LTD. (JP) | 1985-05-28 | — | — | US | disclosed |
| JP-S57106644-A | FARNESENCE DERIVATIVE, MUCOSA STABILIZER COMPRISING IT AS ACTIVE INGREDIENT, AND ITS PREPARATION | KOTOBUKI SEIYAKU KK | 1982-07-02 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120172429-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI- INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | KMT2A 2190/4885SQLE 3584/4885MAPT 725/4885 |
| US-10201510-B2 | Compositions and methods for treatment of neurological symptoms associated with alcohol-withdrawal and for convulsive seizure | ADH1C, ADH1A, CHRNA10 | KMT2A 1291/4885SQLE 217/4885MAPT 295/4885 |
| US-20190284125-A1 | Amine Derivatives of The Beta-Farnesene | FNTA, FNTB, FDPS | KMT2A 1676/4885SQLE 8/4885MAPT 900/4885 |
| US-20080286209-A1 | Compositions and Methods for Treatment of Neurological Symptoms Associated with Alcohol-Withdrawal and for Consulsive Seizure | PNMT, ADH1A, CHRNA10 | KMT2A 1287/4885SQLE 464/4885MAPT 524/4885 |
| US-20210290561-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | TRPV1, CACNA1B, ORAI1 | KMT2A 2190/4885SQLE 3584/4885MAPT 725/4885 |
| US-20220016046-A1 | PERMANENTLY CHARGED SODIUM AND CALCIUM CHANNEL BLOCKERS AS ANTI-INFLAMMATORY AGENTS | CACNA1B, TRPV1, ORAI1 | KMT2A 2196/4885SQLE 3640/4885MAPT 716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.